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In the airways of asthmatic patients, activated fibroblasts account for an excessive matrix
production including proteoglycans (PGs). Transforming growth factor-b (TGFb), metallopro-
teinases (MMPs) and their tissue inhibitors (TIMPs) play key roles in matrix turnover. It is
unclear whether asthma therapy with combination of inhaled glucocorticoids and long-acting
b2-agonists affects metalloproteolytic equilibrium and by that counteracts airway fibrosis.
The effects of the glucocorticoid, budesonide, and the long-acting b2-agonist, formoterol,
on the PG production and the activity of PGs’ main regulators: MMP-3, MMP-9, MMP-2 and
TIMP-1 were investigated in human lung fibroblasts (HFL-1) treated for 24 h with TGFb1
(10 ng/ml) without/with budesonide (109 to 106 M) and/or formoterol (1011 to 106 M).
TGFb1 significantly increased production of PGs and TIMP-1, and the activity of MMP-3, MMP-9
and MMP-2. Concurrent budesonide/formoterol combination counteracted the enhanced: PG
and TIMP-1 production, MMP-9 activity and MMP-9/TIMP-1 ratio, whereas MMP-2 and MMP-3 were
not affected and so their ratios to TIMP-1 were significantly increased. Budesonide or formoterol
alone achieved equal effects as budesonide/formoterol on MMP-9 and MMP-9/TIMP-1 ratio but
hadnoeffects onTIMP-1,MMP-2 orMMP-3. In the formoterol absence, higher budesonide concen-
trations were required to reduce the PG production, whereas formoterol alone had no effects.
These results suggest that the budesonide/formoterol combination enhanced metalloproteo-
lytic activity of human lung fibroblasts via a synergistic decrease of TIMP-1, and that thisedical Faculty of Lund University, the Swedish Medical Research Council (11550) and AstraZeneca.
222 33 14; fax: þ46 46 211 34 17.
n-Thorsson@med.lu.se (G. Westergren-Thorsson).
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1756 L. Todorova et al.mechanism may be involved in the synergistic inhibition of the TGFb1-induced PG production.
This implies that budesonide/formoterol combination therapy can counteract excessive matrix
production and thus pathological airway fibrotic remodeling in asthma.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
In asthma, extensive structural reorganization in airway and
lung tissue occurs, and this is known as airway remodeling. A
prominent characteristic of this process is the formation of
subepithelial fibrosis due to an enhanced deposition of
extracellular matrix (ECM) molecules, particularly collagen,
fibronectin and proteoglycans (PGs). Subepithelial fibrosis,
described as a thickening of the airway reticular basement
membrane, is found in asthma of all severities and correlates
with decline in lung function, attack score and airway
hyperresponsiveness (reviewed in Ref. [1]). A key factor in
the ECM remodeling in asthma is transforming growth factor-
b (TGFb), known to induce the differentiation of fibroblasts
into myofibroblasts and increasing their ECM production.
TGFb reactivity and the number of submucosal fibroblasts
were both shown to correlate with the increased thickness of
the reticular basement membrane in airways of asthmatic
patients (reviewed in Ref. [2]).
Subepithelial fibrosis in asthma may occur as a result of
an imbalance between metalloproteinases (MMPs), which
degrade ECM, and tissue inhibitors of MMPs (TIMPs),
particularly TIMP-1 which is the most widely distributed and
acts on all active MMPs. Increased levels and/or activity of
various MMPs are found in the airways of asthmatic
patients, the most prominent being the gelatinases MMP-
93,4 and also MMP-25,6 and the stromelysin MMP-3.7 These
are further enhanced after allergen challenge, during
asthma exacerbations, and in severe asthma. Importantly,
TIMP levels are also elevated in the airways of patients with
asthma4,5,8,9 and high levels of TIMP-1 are associated with
increased airway fibrosis.8e11 This suggests that patholog-
ical airway remodeling in asthma, resulting in airway
fibrosis, may be a consequence of over-repair mechanisms.
The reversibility of subepithelial fibrosis in the airways
of asthmatic patients and its sensitivity to drug therapy is
an issue of ongoing debate.1 In particular, it is unclear
whether the currently most successful asthma therapy e
combination therapy with inhaled glucocorticoids (GCs) and
long-acting b2-adrenoceptor agonists e may affect devel-
opment of subepithelial fibrosis and whether this effect
may be greater than with inhaled GC monotherapy.
Whereas the beneficial effects of combination therapy on
airway myofibroblast12 and bronchial wall thickness13 in
asthma patients have been recently reported, according to
our knowledge data are scarce on the effects of the
combination therapy on metalloproteolytic balance in the
airways of asthmatics and its effects on ECM deposition.
Here we investigated the effects of the GC, budesonide
(BUD), and the long-acting b2-agonist, formoterol (FORM),
alone and in combination, on the proteolytic activity of
lung fibroblasts which were stimulated with TGFb. We
studied the activity of MMP-9, MMP-2 and MMP-3 and the
production of their main inhibitor TIMP-1. In parallel, weinvestigated the effects of BUD and FORM on the TGFb-
induced PG production which is a target of these MMPs;
predominantly stromelysins (such as MMP-3) but also
gelatinases (such as MMP-9 and MMP-2).14 The contribution
of PGs to subepithelial fibrosis in asthma has not received
much attention although PG levels are increased in the
airways of asthmatic patients15,16 and positively correlate
with patient airway hyperresponsiveness.16,17
Material and methods
Study design
Confluent human fetal lung fibroblast cells, HFL-1
(obtained in passage 12 from American Type Culture
Collection, Rockville, MD, USA) and used in passages 14e22,
were grown in 6- or 24- or 96-well plates in Earle’s Minimal
Essential Medium (Gibco Brl, Paisley, UK) with 10% bovine
donor calf serum, 1% L-glutamine and 1% penicillinestrep-
tomycin at 37 C in a humidified 5% CO2 atmosphere. Prior
to treatment with TGFb1 and drugs (or vehicle), fibroblasts
were starved for 2 h in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 1% donor calf serum and 1%
L-glutamine. Subsequently, cells were incubated for 24 h with
TGFb1 (R&D Systems, Minneapolis, MN, USA) at 10 ng/ml in
0.4% serum concurrently with budesonide (BUD) and/or
formoterol (FORM) (AstraZeneca, Lund, Sweden) across
a concentration range of 1011 to 106 M, or with drug
vehicle (0.1% ethanol). For the PG analysis, fibroblasts were
incubated in MgSO4-poor DMEM (Gibco BRL, Paisley, UK) and
for the last 22 h in the presence of 50 mCi/ml [35S]-sulfate
(PerkinElmer Life Science, Boston, MA, USA). Fibroblasts
incubated in 0.4% serum with drug vehicle were used as
a baseline control.
Immunocytochemical and morphological
characterization of fibroblasts
Fibroblasts were grown to confluence in 4-well chambers,
fixed in 4% paraformaldehyde and permeabilized with 1%
Triton in PBS, washed and incubated with monoclonal
mouse anti-human antibodies for a-smooth muscle actin
(a-SMA). Negative controls were incubated without primary
antibody. Secondary antibody used was goat anti-mouse
Alexa Flour 594 (Molecular Probes, Eugene, OR) and nuclei
were stained with Hoechst (H33342 Sigma Chemical Co.,
St. Louis, MO, USA). Slides were mounted with Cytomation
Fluorescent Mounting Medium (Dako, Glostrup, Denmark)
and analyzed with fluorescence microscopy (Nikon Eclipse
TE 2000-U with Nikon digital camera DXM 1200, Japan). For
stress fibre analysis, Alexa Fluor488 phalloidin probe
diluted in blocking buffer was used and fluorescence
microscope was used to examine the cells.
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PGs produced and released into the cell culture medium
were isolated by anion-exchange chromatography and the
total PG production was measured as [35S]-sulfate incor-
poration into the glycosaminoglycan chains as previously
described.18 The amount of radioactivity for the purified
total PG was quantified and related to the total protein
amount of the respective cell layer.
Protein determination
The cell layer was extracted with 50 mM Tris, 100 mM NaCl,
2 mM MgCl2, 10% glycerol and 1% NP-40, pH 7.4 with pep-
statin A, aprotenin and leupeptin (1 mg/ml). Total protein
amount for the cell layers was determined using the BCA
protein assay kit (Pierce Chemical Co., Rockford, IL, USA).
aSMA mRNA analysis
Total RNA was extracted from the cell layers using RNeasy
kit (Qiagen GmbH, Hilden, Germany) and first strand cDNA
was synthesized using first strand cDNA synthesis kit for
Reverse Transcriptase-Polymerase Chain Reaction (Roche
Applied Science, Indianapolis, USA) followed by real time
PCR measurements using SYBR Green I PCR Master Mix
(Roche Applied Science) as described previously.18 As
a negative control, mRNA samples were used that had not
undergone reverse transcription. A melting curve was per-
formed to determine the melting temperature of the
amplicons, and consequently, the specificity of the PCRs.
Results, related to the internal control (18S), were
analyzed using the Lightcycler (Bromma, Sweden) soft-
ware. Real time-PCRs were performed in duplicates or
triplicates. Primers used were generated using the oligo-
nucleotide design program Primer3 (MIT) (http://frodo.wi.
mit.edu/cgi-bin/primer3/primer3_www.cgi) and ordered
from A/S DNA Technology, Denmark; for a-SMA: forward
50-gaa gga ata gcc acg ctc ag-30 and reverse 50-ttc aat gtc
cca gcc atg ta-30; for 18S: forward 50-cga acg tct gcc cta tca
ac-30 and reverse 50-tgc ctt cct tgg atg tgg ta-30.
a-SMA and TIMP-1 by ELISA
a-SMA protein expression was measured by ELISA. 96-Well
Nunc-Immuno Plate with Maxisorb surface was coated with
polyclonal rabbit anti-a-SMA (Abcam, UK) and blocked with
3% BSA. Cell lysate containing 10 mg of total protein was
added to each well, and bound a-SMA was detected using
a monoclonal mouse anti-human a-SMA (DakoCytomation,
Denmark) and an alkaline phosphatase (AP)-conjugated
secondary antibody (mouse immunoglobulin AP, DakoCyto-
mation, Denmark). 2 mg/ml p-Nitrophenyl Phosphate
(pNPP) dissolved in 1 M diethanolamine, 0.5 mM MgCl2, pH
9.8, was added for development and absorbance was
measured at 405 nm. The concentration of TIMP-1 in the
conditioned media was analyzed by ELISA according to
manufacturer instructions (Amersham, GE Healthcare,
Buckinghamshire, UK) and normalized to the total protein
amount in the corresponding cell layers.Cell proliferation assay
Fibroblast proliferation was assessed using the method of
crystal violet dye as described previously.19 After serum
starvation overnight, cells were incubated with TGFb1 and
the drugs or vehicle for 24 h and 48 h. As a positive control
10% serum was used and 0.4% serum as a negative control.
Proliferation rate was determined spectrophotometrically
at 595 nm.
Gelatin and casein zymography
Conditioned media from treated fibroblasts were
concentrated (Centric YM-10 Millipore, Watford, UK) and
analyzed on Novex polyacrylamide zymogram gels (Invi-
trogen, Stockholm, Sweden). For gelatinase activity,
equal volume of all samples was activated with 1 mM 4-
aminophenyl mercuric acetate (APMA) for 24e72 h and
diluted in TriseGlycine SDS Sample buffer (Invitrogen,
Stockholm, Sweden). The samples were run on 10%
zymogram under non-denaturing conditions according to
the manufacturer instructions (Invitrogen, Stockholm,
Sweden). For caseinolytic activity, samples were pre-
activated with 5 mg/ml trypsin for 30 min at 37 C and
activation was terminated by 2 mM phenyl-methyl-
sulphonylfluoride. The molecular weight corresponding
to the gelatinolytic and caseinolytic areas was esti-
mated using the prestained molecular weight marker
BluePlus2 Prestained Standard (Invitrogen, Stockholm,
Sweden). Bands were analyzed and quantified using
BIORAD’s software Quantity One. All densitometry anal-
yses were related to the total amount protein in each
sample.
For identification of the MMPs, Western blot was per-
formed where preactivated samples were subjected to 10%
TriseGlycine gels for MMP-2 and MMP-9, or 4e12% for MMP-3
(Invitrogen, Stockholm, Sweden). Separated samples were
transferred to PVDF-membranes using electro-blotting.
Primary antibodies used: MMP-2 mouse anti-human mono-
clonal IgG/K, MMP-9 rabbit anti-mouse (Gelatinase B)
polyclonal full length, and rabbit anti-MMP-3 (Chemicon,
Temecula, CA, USA); all diluted 1:1000 in TriseHCl, 150 mM
NaCl, pH 7.5, 0.05% Tween with 1% BSA. Polyclonal
secondary antibodies used: rabbit anti-mouse-HRP for MMP-
2; swine anti-rabbit-HRP for MMP-9, and rabbit anti-mouse-
HRP for MMP-3, all diluted 1:1000 (DakoCytomation,
Glostrup, Denmark). Bands were visualized after develop-
ment with ECL Western Blotting Detection Reagents
(Amersham GE Healthcare).
Statistical analysis
Data are expressed as a percentage of baseline control
where 100% corresponds to baseline conditions (0.4%
serum), and displayed as mean SEM. Effects of TGFb1
were analyzed versus baseline control. Effects of drugs
versus TGFb1 were analyzed as per cent inhibition:
% inhibitionZ 100 100 (D B)/(T B), where T and D
represent treatment with TGFb1 with vehicle or with drugs,
respectively, and B represents baseline control. Statistical
1758 L. Todorova et al.analysis was performed using Astute software 1.5 (DDU
Software, Leeds, UK) by analysis of 99%, 95% and 90%
confidence intervals obtained from one-way analysis of
variance (ANOVA). Differences were considered significant
at p< 0.05.
Results
Fibroblast activation
Proteoglycan production
To activate fibroblasts and to enhance their ECM produc-
tion, cells were incubated with TGFb1 at 10 ng/ml for 24 h.
Control fibroblasts (exposed to 0.4% serum) appeared
elongated in a spindle-like shape with long cytoplasmic
projections, whereas fibroblasts treated with TGFb1
appeared in a rounded form with a more compact cyto-
plasm and with more well-defined stress fibres.
The total PG production increased with increasing TGFb1
concentrations and a 2.5-fold increase was obtained at
10 ng/ml (p< 0.01). This increase was reduced in
a concentration-dependent manner by BUD 109 to 106 M
(Fig. 1) with a significant 35% reduction achieved at 106 M
(p< 0.05). FORM 1011 to 106 M had no inhibitory effects,
but when applied together with BUD in a 100:1 BUD:FORM
ratio (which approximately reflects the clinical dose ratio),
it enhanced the effect of BUD. Accordingly, a significant
39% reduction (p< 0.05) was achieved by BUD 108 M with
FORM 1010 M and a 54% reduction (p< 0.01) by BUD 106 M
with FORM 108 M.
For subsequent experiments, we chose the lowest drug
concentrations that when used in combination exerted
significant inhibition of the total PG production, i.e. BUD at
108 M and FORM at 1010 M. These concentrations are
considered clinically relevant. We have found that at these
concentrations, the BUD and FORM combination also
reduced the total baseline PG production (cells incubated
with 0.4% serum; data not shown) and that this accountedTotal extracellula
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Figure 1 The total production of extracellular proteoglycans in
growth factor-b1 (TGFb1; 10 ng/ml) for 24 h (versus incubation wi
budesonide 109 M (B9) e BUD 106 M (B6), or FORM 1011 M (F11)
normalized to the total protein amount in the corresponding
serumZ 100%); for all bars p< 0.01 versus control (0.4% serum); *for approximately one quarter of the reduction seen in the
presence of TGFb1.
Differentiation and proliferation
The effects of BUD and FORM on TGFb1-induced fibroblast
differentiation and proliferation were analyzed to assess
whether they contributed to the effects on PG production.
For the assessment of fibroblast differentiation towards
active myofibroblasts, the myofibroblast marker a-SMA was
analyzed. The fraction of cells stained for a-SMA increased
with increasing TGFb1 concentration and exposure time.
With TGFb1 at 10 ng/ml and 24 h incubation time, the
majority of cells (72%) showed a strong a-SMA staining
compared with 23% of cells exposed to 0.4% serum
(p< 0.01). Measurements of a-SMA mRNA and protein levels
(ELISA) confirmed increased synthesis of a-SMA in TGFb1-
stimulated cells; a-SMA mRNA increased 7-fold and a-SMA
protein 1.8-fold (p< 0.01 for both) but this increase was
not counteracted by concurrent treatment with BUD 108 M
and/or FORM 1010 M (Fig. 2A).
Neither TGFb1 alone (10 ng/ml) nor together with BUD
108 M and/or FORM 1010 M had significant effects on
fibroblast proliferation after 24 h or 48 h incubation
(Fig. 2B) whereas proliferation was increased significantly
(1.3-fold) after 24 h incubation with 10% serum used as
a positive control.18
Metalloproteinases
MMP-9
Gelatin zymography showed enzymatic activity of both
MMP-9 and MMP-2 in the fibroblast-conditioned medium
and Western blot analysis confirmed the presence of
enzyme pro-forms and high molecular weight complexes
for both MMPs (Fig. 3A). For MMP-9, quantification by
densitometry showed that TGFb1 significantly increased
the active form (82 kDa) 3.8-fold (p< 0.05) (Fig. 3B) as
well as the pro-enzyme (92 kDa) and high molecularr proteoglycan pool
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Figure 2 Characterization of human lung fibroblasts (HFL-1)
stimulatedwith transforming growth factor b1 (TGFb1; 10 ng/ml)
for 24 h (versus incubation with 0.4% serum), and the effects
of concurrent treatment with budesonide 108 M (B8) and/or
formoterol 1010 M (F10). (A) a-smooth muscle actin expression
at mRNA level (nZ 6e7; light bars) and protein level (ELISA)
normalized to the total protein amount in the corresponding
cell layers (nZ 2; dark bars). (B) fibroblast proliferation after
24 h (light bars) or 48 h (dark bars) incubation (nZ 3). Data are
expressed as a percentage of control (0.4% serumZ 100%);
þþp< 0.01 versus 0.4% serum (there are no statistically
significant differences versus TGFb1).
Budesonide/formoterol effects on MMPs/TIMP-1 ratio 1759weight complexes (around 200 kDa) 4e6-fold (p< 0.05).
All forms of MMP-9 detected in the presence of TGFb1
were reduced by both BUD and FORM alone and in
combination to levels that were not significantly different
from those at baseline conditions (0.4% serum). Compared
with TGFb1-induced response, the active enzyme was
reduced 76% by BUD, 49% by FORM and 84% by the BUD/
FORM combination (p< 0.01 for all; Fig. 3B), and the pro-
form of the enzyme by 70e90% for all drug treatments
(p< 0.01). BUD alone and in combination with FORM also
reduced the baseline activity of MMP-9 (cells incubated
with 0.4% serum; data not shown) and this accounted for
approximately one half of the reduction seen in the
presence of TGFb1.
MMP-2
The activity of MMP-2 at baseline conditions (0.4% serum)
was approximately 10-fold greater than that of MMP-9
(Fig. 3A), which is in agreement with constitutive expres-
sion of MMP-2 by lung fibroblasts. At baseline conditions,
MMP-2 was detected as a pro-form (72 kDa) and as active
enzyme at 62 kDa (Fig. 3A). Both forms were significantly
increased by TGFb1; the pro-form enzyme 4.8-fold
(p< 0.05) and the active enzyme 3.3-fold (p< 0.01;
Fig. 3C). Concurrent treatment with BUD and FORM alone
and in combination had no effect on either the active form
(Fig. 3C) or the pro-form of the MMP-2.MMP-3
Casein zymography followed by Western blot revealed both
the presence and enzymatic activity of MMP-3 in the
conditioned medium of fibroblasts at control conditions (in
0.4% serum) and after stimulation with TGFb1. The pro-
enzyme appeared as a double band at 59 kDa and 57 kDa
(representing a glycosylated and non-glycosylated form,
respectively), the active enzyme as a band at 45 kDa, and
a complexed form as a band at around 100 kDa (Fig. 4A).
Densitometric analysis revealed that TGFb1 increased the
active band 1.6-fold (p< 0.05) (Fig. 4B), and a 1.5e2.0-fold
increase was also seen for all the other MMP-3 forms
detected. Concurrent treatment with BUD and/or FORM did
not significantly affect the active MMP-3 or the other MMP-3
forms, except for 59 kDa pro-enzyme which was further
enhanced by BUD/FORM combination treatment [from the
2.0-fold increase by TGFb1 (p< 0.05) to a 2.8-fold increase
after addition of BUD/FORM (p< 0.05)].
TIMP-1
As evaluated by ELISA, TGFb1 significantly increased TIMP-1
protein (1.6-fold, p< 0.01). Concurrent treatment with
BUD had no effect and the further 45% increase by FORM
was not statistically significant (p> 0.1). However, treat-
ment with the BUD/FORM combination significantly
(p< 0.05) and completely counteracted the TGFb1-induced
TIMP-1 increase (Fig. 5).
Metalloproteolytic equilibrium
Considering the 3e4-fold increase of active MMP-9 and
MMP-2 by TGFb1 and only 1.6-fold increase of TIMP-1
protein, TGFb1 exposure led to a pro-proteolytic environ-
ment; with a 2-fold increase of the ratios of MMP-9/TIMP-1
(p< 0.1) and MMP-2/TIMP-1 (p< 0.01) as compared to the
baseline conditions (exposure to 0.4% serum). The increase
of MMP-9/TIMP-1 ratio was completely abolished by
concurrent treatment with BUD and FORM alone and in
combination (Fig. 6A). In contrast, the increase of MMP-2/
TIMP-1 ratio was further potentiated by BUD/FORM
combination treatment (but not by either drug alone),
reaching a 3-fold increase when compared to baseline
conditions (p< 0.01; p< 0.05 versus TGFb1 alone; Fig. 6B).
In contrast to MMP-9 and MMP-2, TGFb1 increased active
MMP-3 to the same extent as it increased TIMP-1 protein
(1.6-fold in both cases) and thus did not affect the ratio of
MMP-3/TIMP-1. This ratio was not affected by concurrent
BUD or FORM treatment, whereas BUD/FORM combination
increased it 2.5-fold as compared to baseline conditions
(p< 0.05; p< 0.1 versus TGFb1 alone; Fig. 6C).
Discussion
In this study, we have shown that stimulation of human lung
fibroblasts with TGFb1 resulted, along with increased a-SMA
expression, in increased production of PGs and TIMP-1
protein as well as enhanced activities of gelatinases MMP-9
and MMP-2 and the stromelysin MMP-3. We have further
shown that concurrent BUD/FORM combination treatment
counteracted the TGFb1-induced production of PGs and
TIMP-1,aswell asenhancedMMP-9activityandMMP-9/TIMP-1
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Figure 3 The production and activity of metalloproteinase-9
(MMP-9) and -2 (MMP-2) by human lung fibroblasts (HFL-1)
stimulated by transforming growth factor-b1 (TGFb1; 10 ng/ml)
for 24 h (versus 0.4% serum) and the effects of concurrent
treatment with budesonide 108 M (B8) and/or formoterol
1010 M (F10). (A) Representative gelatin zymogram and
Western blot (WB) using equal volume samples, revealing both
the presence and the enzymatic activity of MMP-9 and MMP-2 in
the cell culture medium. For MMP-9, the pro-form enzyme is
visible as a band at 92 kDa, the active enzyme as a band at
82 kDa, and high molecular weight complexes at around
200 kDa. For MMP-2, the pro-form enzyme is visible as a band at
72 kDa and the active enzyme as a band at 62 kDa. In (B) and
(C) data show enzyme activity measured by densitometric
analysis of active bands and normalized to the total protein
concentration in each sample: 82 kDa for MMP-9 (nZ 3) and
62 kDa for MMP-2 (nZ 4). In (B) and (C) data are expressed as
a percentage of control (0.4% serumZ 100%); þp< 0.05,
pþþ< 0.01 versus 0.4% serum; and **p< 0.01 versus TGFb1.
1760 L. Todorova et al.ratio. In contrast, increased a-SMA expression and activity
of MMP-2 and MMP-3 were not affected by BUD/FORM
combination while MMP-2/TIMP-1 and MMP-3/TIMP-1 ratios
were significantly increased. TGFb1-induced MMP-9 activity
and enhanced MMP-9/TIMP-1 ratio was as effectively coun-
teracted by BUD or FORM alone as by the BUD/FORM combi-
nation, whereas neither BUD nor FORM alone affected the
activity of MMP-2 or MMP-3 and the production of TIMP-1.
Moreover, higher concentrations of BUD were required to
reduce the PG production than when BUD was used together
with FORM, although FORM had no effect on its own. These
results suggest that the inhibitory, synergistic effects ofBUD/FORM combination treatment on TGFb1-induced PG
production may involve increased metalloproteolytic turn-
over of PGs through a synergistic decrease of TIMP-1.
We have chosen the human fetal lung fibroblasts, HFL-1,
to address the aims of the present study. These cells have
been previously validated as suitable to study the differ-
entiation of lung fibroblast into myofibroblasts and their
ECM production under exposure to TGFb, which is regarded
as crucial for the development of subepithelial fibrosis in
asthma. These cells show similar morphology and produc-
tion of connective tissue, including PGs, as primary human
bronchial fibroblasts derived from central bronchial lung
biopsies from human subjects.20,21
We have investigated a broad range of BUD (109 to
106 M) and FORM (1011 to 106 M) concentrations on the
total PG production. The drugs were combined in a 100:1
ratio (BUD:FORM), which approximately reflects dose ratio
of these drugs in asthma therapy. For further analyses we
chose BUD 108 M, and consequently FORM 1010 M, which
reflects the concentration of BUD in airway and lung tissue
some hours after inhalation of a moderate dose.22
The total PG production by TGFb1-stimulated lung
fibroblasts was decreased by BUD in a concentration-
dependent manner, and while FORM had no effect on its
own, it potentiated the effect of BUD, suggesting syner-
gistic drug interaction. This synergistic effect regards
predominantly the TGFb1-induced PG production since the
reduction of the baseline production by the drug combi-
nation was responsible only for approximately one quarter
of the reduction in the presence of TGFb1. The drugs,
either alone or in combination, did not affect TGFb1-
induced fibroblast differentiation into more active myofi-
broblast, or fibroblast proliferation. Altogether, these
results resemble very closely our earlier findings on the
effects of BUD and FORM on PG production in HFL-1 fibro-
blasts stimulated with 10% serum.18
PGs are a large component of ECM and are involved in
many pathophysiological processes that occur in the ECM.
They modulate inflammatory response, influence tissue
repair and remodeling, maintain fibre network structure
and function, and affect fluid balance and consequently
tissue resilience and mechanics.23 Total PG levels are
increased in the airways of asthmatic patients.15,16 An
increased production of PGs by bronchial fibroblasts from
asthmatic patients was associated with increased patient
airway hyperresponsivness,17 and a positive correlation
between the enhanced bronchial subepithelial deposition
of some specific PGs and airway hyperresponsiveness was
found in patients with mild asthma.16
The major endogenous factor leading to airway ECM
remodeling in asthma is regarded an imbalance between
activity of MMPs and TIMPs, and especially between gelat-
inase MMP-9 and TIMP-1.3 The level and/or activity of MMP-
9 were shown to be increased in asthma patients’
sputum4,5,9 and bronchoalveolar lavage fluid,24 and
increased further after allergen challenge,4,25 during
asthma exacerbations,6,26 and in severe asthma.4 MMP-9
immunoreactivity in subepithelial basement membrane was
also associated with asthma severity.27 A direct effect of
MMPs is ECM degradation, which may counteract formation
of airway fibrosis. However, an excessive degradation over
a longer period of time may also result in a feedback of
AB Active MMP-3
Casein zymogram WB
100
0.4
% 
se
rum
TG
Fβ1
TG
Fβ1
+B
8
TG
Fβ1
+F
10
TG
Fβ1
+B
8+
F1
0
MMP-3
59
57
45
16
100
140
160
180
200
120
220
+ +
++ ++
TGFβ1 TGFβ1+B8 TGFβ1+F10 TGFβ1+B8+F10
%
 
c
o
n
t
r
o
l
Figure 4 The production and activity of metalloproteinase-3
(MMP-3) by human lung fibroblasts (HFL-1) stimulated by
transforming growth factor-b1 (TGFb1; 10 ng/ml) for 24 h
(versus 0.4% serum), and the effects of concurrent treatment
with budesonide 108 M (B8) and/or formoterol 1010 M (F10).
(A) Representative casein zymogram and Western blot (WB)
using equal volume samples, revealing both the presence and
the enzymatic activity of MMP-3 in the cell culture medium.
The pro-form enzyme is visible as a double band at 59 kDa and
57 kDa, the active enzyme as a band at 45 kDa, and a com-
plexed form as a band at around 100 kDa. (B) Activity of MMP-3
measured by densitometric analysis of the 45-kDa band and
normalized to the total protein concentration in each sample.
In (B) data (nZ 3) are expressed as a percentage of control
(0.4% serumZ 100%); þp< 0.05, pþþ< 0.01 versus 0.4% serum
(there are no significant differences versus TGFb1).
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Figure 5 The production (ELISA) of extracellular tissue
inhibitor of metalloproteinases-1 (TIMP-1) by human lung
fibroblasts (HFL-1) stimulated by transforming growth factor-
b1 (TGFb1; 10 ng/ml) for 24 h (versus 0.4% serum) and the
effects of concurrent treatment with budesonide 108 M (B8)
and/or formoterol 1010 M (F10). Data (nZ 4) were normalized
to the total protein amount in the corresponding cell layers and
expressed as a percentage of control (0.4% serumZ 100%);
þp< 0.05, pþþ< 0.01 versus 0.4% serum; and *p< 0.05 versus
TGFb1.
Budesonide/formoterol effects on MMPs/TIMP-1 ratio 1761over-repair cycles, leading to increased synthesis and
deposition of ECM. Indeed, the levels of TIMP-1 are also
elevated in the airways of asthmatic patients4,5,8,9 and
TIMP-1 molar concentrations often exceed the concentra-
tions of MMP-9 and other MMPs.8e10 Furthermore, high
levels of TIMP-1 in sputum of asthmatic patients are asso-
ciated with increased airway obstruction9 and with airway
structural changes in patients with severe asthma.10,11
These findings suggest that although TIMP-1 protects airway
tissue against enhanced MMP activity, its increase may also
be pathogenic and lead to enhanced airway fibrosis. It is
conceivable that for a proper healing and repair processes
in the airways, both a pro- and an anti-proteolytic envi-
ronment is required at different stages of this process.
Importantly, the airway fibrotic remodeling in asthma
suggests an over-repair as a consequence of a disturbance
of this process.
In the present study, the active gelatinases MMP-9 and
MMP-2 were 3e4-fold increased by TGFb1 and their ratiosto TIMP-1 protein were increased 2-fold. For MMP-9, these
changes were effectively counteracted by BUD and FORM,
both alone and in combination. However, such effects were
not observed for MMP-2; in contrary, its ratio to TIMP-1 was
further increased by BUD/FORM combination while either
drug alone had no effect. Similarly, the ratio of active MMP-
3 to TIMP-1 protein was increased by BUD/FORM combina-
tion treatment although it was not increased by TGFb1
alone or together with either BUD or FORM. The increased
ratio of these MMPs to TIMP-1 was caused by the fact that
BUD/FORM combination treatment completely counter-
acted the TGFb1-induced increase of TIMP-1 while it had no
effects on MMP-2 or MMP-3 activity. Although we do not
know whether TIMP-1 equally inhibits various MMPs, these
results suggest that a decrease of TIMP-1 by BUD/FORM
combination results in an enhanced activity of MMP-2 and
MMP-3, which then may lead to an increased turnover of
PGs. Thus, this mechanism may be involved in the inhibition
of the TGFb1-induced PG production by the BUD/FORM
combination.
The effects of BUD and FORM on the production of PGs
and TIMP-1 at the low/moderate drug concentrations
investigated appeared to be synergistic as neither BUD nor
FORM alone had any effects at these concentrations. We
have previously shown that a synergistic decrease in the
total PG production by BUD and FORM in these cells (stim-
ulated by 10% serum) was dependent on the presence of
functional GC receptors and b-adrenoceptors.18 These
effects can be explained by the ability of b2-agonists to
enhance activation and nuclear translocation of GC recep-
tors and, as a consequence, affect GC-regulated gene
transcription,28,29 as well as by the ability of GCs to
increase b2-adrenoceptor expression and signalling
(reviewed in Ref. [29]). The latter may counteract desen-
sitisation and downregulation of b2-adrenoceptors by
TGFb1.30
In conclusion, these results suggest that the BUD/FORM
combination enhanced metalloproteolytic activity of
human lung fibroblasts via a synergistic decrease of TIMP-1,
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Figure 6 The effects of transforming growth factor-b1
(TGFb1; 10 ng/ml; 24 h incubation) and the concurrent treat-
ment with budesonide 108 M (B8) and/or formoterol 1010 M
(F10) on the equilibrium (shown as ratio) between active
metalloproteinases (MMP-9, MMP-2 and MMP-3) and tissue
inhibitor of metalloproteinases-1 (TIMP-1) protein in human
lung fibroblasts (HFL-1) incubation medium, as compared to
control (0.4% serum) conditions (shown here as the ratioZ 1).
þp< 0.05, pþþ< 0.01 versus 0.4% serum; and *p< 0.05 versus
TGFb1.
1762 L. Todorova et al.and that this mechanism may be involved in the synergistic
inhibition of the TGFb1-induced PG production by BUD/
FORM treatment. This implies that BUD/FORM combination
therapy can counteract excessive ECM production and
deposition and thus pathological airway fibrotic remodeling
in asthma. Extension of these findings to other ECM mole-
cules, and investigation of lung fibroblasts from patients
with asthma are warranted.
Acknowledgements
We greatly appreciate the excellent technical assistance of
Susanne Jonsson BSc and Marie Wildt BSc. We also thank
Professor Dick Heinega˚rd for kindly providing us with anti-
bodies for MMP-2, MMP-3 and MMP-9. This study was sup-
ported by the Medical Faculty of Lund University, the
Swedish Medical Research Council (11550) and
AstraZeneca.Conflict of interest statement
LT has received a grant from AstraZeneca and financial
support to ERS and ATS meetings. EG and AM-L are
employees of AstraZeneca.References
1. Tang ML, Wilson JW, Stewart AG, Royce SG. Airway remodelling
in asthma: current understanding and implications for future
therapies. Pharmacol Ther 2006;112:474e88.
2. Howell JE, McAnulty RJ. TGF-beta: its role in asthma and
therapeutic potential. Curr Drug Targets 2006;7:547e65.
3. Ohbayashi H, Shimokata K. Matrix metalloproteinase-9 and
airway remodeling in asthma. Curr Drug Targets Inflamm
Allergy 2005;4:177e81.
4. Mattos W, Lim S, Russell R, Jatakanon A, Chung KF, Barnes PJ.
Matrix metalloproteinase-9 expression in asthma: effect of
asthma severity, allergen challenge, and inhaled corticoste-
roids. Chest 2002;122:1543e52.
5. Cataldo D, Munaut C, Noel A, Frankenne F, Bartsch P,
Foidart JM, et al. MMP-2- and MMP-9-linked gelatinolytic
activity in the sputum from patients with asthma and chronic
obstructive pulmonary disease. Int Arch Allergy Immunol 2000;
123:259e67.
6. Suzuki R, Kato T, Miyazaki Y, Iwata M, Noda Y, Takagi K, et al.
Matrix metalloproteinases and tissue inhibitors of matrix
metalloproteinases in sputum from patients with bronchial
asthma. J Asthma 2001;38:477e84.
7. Lemjabbar H, Gosset P, Lamblin C, Tillie I, Hartmann D,
Wallaert B, et al. Contribution of 92 kDa gelatinase/type IV
collagenase in bronchial inflammation during status asthmati-
cus. Am J Respir Crit Care Med 1999;159:1298e307.
8. Mautino G, Henriquet C, Jaffuel D, Bousquet J, Capony F.
Tissue inhibitor of metalloproteinase-1 levels in bron-
choalveolar lavage fluid from asthmatic subjects. Am J Respir
Crit Care Med 1999;160:324e30.
9. Vignola AM, Riccobono L, Mirabella A, Profita M, Chanez P,
Bellia V, et al. Sputum metalloproteinase-9/tissue inhibitor of
metalloproteinase-1 ratio correlates with airflow obstruction in
asthma and chronic bronchitis. Am J Respir Crit Care Med
1998;158:1945e50.
10. Matsumoto H, Niimi A, Takemura M, Ueda T, Minakuchi M,
Tabuena R, et al. Relationship of airway wall thickening to an
imbalance between matrix metalloproteinase-9 and its inhib-
itor in asthma. Thorax 2005;60:277e81.
11. Vignola AM, Paganin F, Capieu L, Scichilone N, Bellia M,
Maakel L, et al. Airway remodelling assessed by sputum and
high-resolution computed tomography in asthma and COPD.
Eur Respir J 2004;24:910e7.
12. Kelly M, O’Connor T, Leigh R, Otis J, Gauvreau G,
Gauldie J, et al. Inhaled budesonide/formoterol combina-
tion therapy significantly attenuates allergen-induced
increases in airway myofibroblasts. Eur Respir J 2007;
30(Suppl. 51):137s (P903).
13. Capraz F, Kunter E, Cermik H, Ilvan A, Pocan S. The effect
of inhaled budesonide and formoterol on bronchial remod-
eling and HRCT features in young asthmatics. Lung 2007;185:
89e96.
14. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Bir-
kedal-Hansen B, DeCarlo A, et al. Matrix metalloproteinases:
a review. Crit Rev Oral Biol Med 1993;4:197e250.
15. Roberts CR, Burke AK. Remodelling of the extracellular matrix
in asthma: proteoglycan synthesis and degradation. Can Respir
J 1998;5:48e50.
Budesonide/formoterol effects on MMPs/TIMP-1 ratio 176316. Huang J, Olivenstein R, Taha R, Hamid Q, Ludwig M. Enhanced
proteoglycan deposition in the airway wall of atopic asth-
matics. Am J Respir Crit Care Med 1999;160:725e9.
17. Westergren-Thorsson G, Chakir J, Lafreniere-Allard MJ,
Boulet LP, Tremblay GM. Correlation between airway respon-
siveness and proteoglycan production by bronchial fibroblasts
from normal and asthmatic subjects. Int J Biochem Cell Biol
2002;34:1256e67.
18. Todorova L, Gu¨rcan E, Miller-Larsson A, Westergren-
Thorsson G. Lung fibroblast proteoglycan production induced
by serum is inhibited by budesonide and formoterol. Am
J Respir Cell Mol Biol 2006;34:92e100.
19. Westergren-Thorsson G, O¨nnervik PO, Fransson LA˚,
Malmstro¨m A. Proliferation of cultured fibroblasts is inhibited
by L-iduronate-containing glycosaminoglycans. J Cell Physiol
1991;147:523e30.
20. Westergren-Thorsson G, Malmstro¨m J, Marko-Varga G. Pro-
teomics e the protein expression technology to study
connective tissue biology. J Pharm Biomed Anal 2001;24:
815e24.
21. Malmstro¨m J, Westergren-Thorsson G, Marko-Varga G. A pro-
teomic approach to mimic fibrosis disease evolvement by an in
vitro cell line. Electrophoresis 2001;22:1776e84.
22. Van den Bosch JM, Westermann CJ, Aumann J, Edsba¨cker S,
To¨nnesson M, Selroos O. Relationship between lung tissue and
blood plasma concentrations of inhaled budesonide. Biopharm
Drug Dispos 1993;14:455e9.23. Iozzo R. Matrix proteoglycans: from molecular design to
cellular function. Annu Rev Biochem 1998;67:609e52.
24. Mautino G, Oliver N, Chanez P, Bousquet J, Capony F. Increased
release of matrix metalloproteinase-9 in bronchoalveolar
lavage fluid and by alveolar macrophages of asthmatics. Am
J Respir Cell Mol Biol 1997;17:583e91.
25. Kelly EA, Busse WW, Jarjour NN. Increased matrix metal-
loproteinase-9 in the airway after allergen challenge. Am
J Respir Crit Care Med 2000;162:1157e61.
26. Lee YC, Lee HB, Rhee YK, Song CH. The involvement of matrix
metalloproteinase-9 in airway inflammation of patients with
acute asthma. Clin Exp Allergy 2001;31:1623e30.
27. Wenzel SE, Balzar S, Cundall M, Chu HW. Subepithelial base-
ment membrane immunoreactivity for matrix metal-
loproteinase 9: association with asthma severity, neutrophilic
inflammation, and wound repair. J Allergy Clin Immunol 2003;
111:1345e52.
28. Giembycz MA, Kaur M, Leigh R, Newton R. A Holy Grail of
asthma management: toward understanding how long-acting
b2-adrenoceptor agonists enhance the clinical efficacy of
inhaled corticosteroids. Br J Pharmacol 2008;153:1094e104.
29. Barnes PJ. Scientific rationale for inhaled combination therapy
with long-acting b2-agonists and corticosteroids. Eur Respir
J 2002;19:182e91.
30. Mak JC, Rousell J, Haddad EB, Barnes PJ. Transforming growth
factor-beta1 inhibits beta2-adrenoceptor gene transcription.
Naunyn Schmiedeberg’s Arch Pharmacol 2000;362:520e5.
